Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Sonja Zweegman"'
Autor:
Pieter Langerhorst, Joannes F M Jacobs, Martijn M. VanDuijn, Christie P. M. Verkleij, Marina Zajec, Yolanda B. de Rijke, Somayya Noori, Patricia W. C. Bosman, Sonja Zweegman, Theo M. Luider, Niels W.C.J. van de Donk
Publikováno v:
Clinical Chemistry and Laboratory Medicine, 59(12), 1963-1971. De Gruyter
Noori, S, Verkleij, C P M, Zajec, M, Langerhorst, P, Bosman, P W C, de Rijke, Y B, Zweegman, S, Vanduijn, M, Luider, T, van de Donk, N W C J & Jacobs, J F M 2021, ' Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: The laboratory solution to eliminate interference ', Clinical Chemistry and Laboratory Medicine, vol. 59, no. 12, pp. 1963-1971 . https://doi.org/10.1515/cclm-2021-0399
Clinical Chemistry and Laboratory Medicine, 59, 12, pp. 1963-1971
Clinical Chemistry and Laboratory Medicine, 59, 1963-1971
Clinical Chemistry and Laboratory Medicine, 59(12), 1963-1971. Walter de Gruyter GmbH
Noori, S, Verkleij, C P M, Zajec, M, Langerhorst, P, Bosman, P W C, de Rijke, Y B, Zweegman, S, Vanduijn, M, Luider, T, van de Donk, N W C J & Jacobs, J F M 2021, ' Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: The laboratory solution to eliminate interference ', Clinical Chemistry and Laboratory Medicine, vol. 59, no. 12, pp. 1963-1971 . https://doi.org/10.1515/cclm-2021-0399
Clinical Chemistry and Laboratory Medicine, 59, 12, pp. 1963-1971
Clinical Chemistry and Laboratory Medicine, 59, 1963-1971
Clinical Chemistry and Laboratory Medicine, 59(12), 1963-1971. Walter de Gruyter GmbH
Objectives The therapeutic monoclonal antibody (t-mAb) daratumumab, used to treat multiple myeloma (MM) patients, interferes with routine, electrophoretic based M-protein diagnostics. Electrophoretic response assessment becomes increasingly difficult
Autor:
Sonja Zweegman, Anne T. Gelderloos, Esther C.W. Breij, Inger S. Nijhof, Tuna Mutis, Hilma J. van der Horst, Marije B. Overdijk, Martine E D Chamuleau
Publikováno v:
van der Horst, H J, Gelderloos, A T, Chamuleau, M E D, Breij, E C W, Zweegman, S, Nijhof, I S, Overdijk, M B & Mutis, T 2021, ' Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma ', Blood, vol. 5, no. 8, pp. 2165-2172 . https://doi.org/10.1182/BLOODADVANCES.2020003731
Blood Adv
Blood, 5(8), 2165-2172. American Society of Hematology
Blood Adv
Blood, 5(8), 2165-2172. American Society of Hematology
Apoptosis induction by death receptor (DR)-specific agonistic antibodies is a potentially effective antitumor therapy. Nonetheless, to date, all conventional DR-targeting antibodies that induce apoptosis via FcγR-dependent DR clustering failed to sh
Publikováno v:
Hemato, Vol 2, Iss 7, Pp 116-130 (2021)
In the 2010s, immunotherapy revolutionized the treatment landscape of multiple myeloma. CD38-targeting antibodies were initially applied as monotherapy in end-stage patients, but are now also approved by EMA/FDA in combination with standards-of-care
Autor:
Marion Koopmans, Inger S. Nijhof, Patricia W. C. Bosman, Tuna Mutis, Niels W.C.J. van de Donk, Sonja Zweegman, Kristine A. Frerichs, Guus F. Rimmelzwaan, Andries C. Bloem, Pieter L. A. Fraaij, Jeroen F. van Velzen
Publikováno v:
Haematologica
Frerichs, K A, Bosman, P W C, van Velzen, J F, Fraaij, P L A, Koopmans, M P G, Rimmelzwaan, G F, Nijhof, I S, Bloem, A C, Mutis, T, Zweegman, S & van de Donk, N W C J 2020, ' Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients ', Haematologica, vol. 105, no. 6, e302-e306, pp. E302-E306 . https://doi.org/10.3324/haematol.2019.231860
Haematologica, 105(6), E302-E306. Ferrata Storti Foundation
Haematologica, 105(6):e302-e306, E302-E306. Ferrata Storti Foundation
Frerichs, K A, Bosman, P W C, van Velzen, J F, Fraaij, P L A, Koopmans, M P G, Rimmelzwaan, G F, Nijhof, I S, Bloem, A C, Mutis, T, Zweegman, S & van de Donk, N W C J 2020, ' Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients ', Haematologica, vol. 105, no. 6, e302-e306, pp. E302-E306 . https://doi.org/10.3324/haematol.2019.231860
Haematologica, 105(6), E302-E306. Ferrata Storti Foundation
Haematologica, 105(6):e302-e306, E302-E306. Ferrata Storti Foundation
Autor:
Mashhour Hosny, Sonja Zweegman, Christie P. M. Verkleij, Kristine A. Frerichs, Niels W.C.J. van de Donk, Jort J. van der Schans, Tuna Mutis
Publikováno v:
Hosny, M, Verkleij, C P M, van der Schans, J, Frerichs, K A, Mutis, T, Zweegman, S & van de Donk, N W C J 2021, ' Current state of the art and prospects of t cell-redirecting bispecific antibodies in multiple myeloma ', Journal of Clinical Medicine, vol. 10, no. 19, 4593 . https://doi.org/10.3390/jcm10194593
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 10, Iss 4593, p 4593 (2021)
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 10, Iss 4593, p 4593 (2021)
Multiple myeloma (MM) patients eventually develop multi-drug-resistant disease with poor survival. Hence, the development of novel treatment strategies is of great importance. Recently, different classes of immunotherapeutic agents have shown great p
Autor:
Walter M Gregory, Annemiek Broijl, Pieter Sonneveld, Rebecca Wijers, Reno Debets, Sonja Zweegman, Dora Hammerl, Bronno van der Holt, Rowan Kuiper, Hayri E. Balcioglu, Pim G.N.J. Mutsaers, Mark van Duin
Publikováno v:
Mutsaers, P, Balcioglu, H E, Kuiper, R, Hammerl, D, Wijers, R, van Duin, M, van der Holt, B, Broijl, A, Gregory, W, Zweegman, S, Sonneveld, P & Debets, R 2021, ' V-domain ig suppressor of t cell activation (Vista) expression is an independent prognostic factor in multiple myeloma ', Cancers, vol. 13, no. 9, 2219 . https://doi.org/10.3390/cancers13092219
Cancers, 13(9):2219. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers
Volume 13
Issue 9
Cancers, Vol 13, Iss 2219, p 2219 (2021)
Cancers, 13(9):2219. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers
Volume 13
Issue 9
Cancers, Vol 13, Iss 2219, p 2219 (2021)
Multiple myeloma (MM) is characterized by loss of anti-tumor T cell immunity. Despite moderate success of treatment with anti-PD1 antibodies, effective treatment is still challenged by poor T cell-mediated control of MM. To better enable identificati
Autor:
Guus A.M.S. van Dongen, Henk M.W. Verheul, Sonja Zweegman, Ronald Boellaard, Marc C. Huisman, Danielle J. Vugts, C. Willemien Menke-van der Houven van Oordt, Otto S. Hoekstra, Adriaan A. Lammertsma, Dennis Heijtel, Josée M. Zijlstra, Henrica C.W. de Vet, Yvonne W. S. Jauw
Publikováno v:
Molecular Imaging and Biology
Jauw, Y W S, Heijtel, D F, Zijlstra, J M, Hoekstra, O S, de Vet, H C W, Vugts, D J, Verheul, H M, Boellaard, R, Zweegman, S, van Dongen, G A M S, der Houven van Oordt, C W M, Lammertsma, A A & Huisman, M C 2018, ' Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies : an Analysis Based on Count-Reduced Clinical Images ', Molecular Imaging and Biology, vol. 20, no. 6, pp. 1025-1034 . https://doi.org/10.1007/s11307-018-1200-4
Molecular Imaging and Biology, 20(6), 1025-1034. SPRINGER
Molecular Imaging and Biology, 20(6), 1025-1034. Springer New York
Jauw, Y W S, Heijtel, D F, Zijlstra, J M, Hoekstra, O S, de Vet, H C W, Vugts, D J, Verheul, H M, Boellaard, R, Zweegman, S, van Dongen, G A M S, der Houven van Oordt, C W M, Lammertsma, A A & Huisman, M C 2018, ' Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies : an Analysis Based on Count-Reduced Clinical Images ', Molecular Imaging and Biology, vol. 20, no. 6, pp. 1025-1034 . https://doi.org/10.1007/s11307-018-1200-4
Molecular Imaging and Biology, 20(6), 1025-1034. SPRINGER
Molecular Imaging and Biology, 20(6), 1025-1034. Springer New York
Purpose Positron emission tomography (PET) with Zirconium-89 (Zr-89)-labeled antibodies can be used for in vivo quantification of antibody uptake. Knowledge about measurement variability is required to ensure correct interpretation. However, no clini
Autor:
Ida H. Hiemstra, Hilma J. van der Horst, Martine E.D. Chamuleau, A. Vera de Jonge, Margaretha G. M. Roemer, Tuna Mutis, Hendrik F. van Essen, Daniella R. A. I. Berry, Anne T. Gelderloos, Nathalie J. Hijmering, Sonja Zweegman, Daphne de Jong, Esther C.W. Breij
Publikováno v:
Blood Cancer Journal
Blood cancer journal, 11(2):38. Nature Publishing Group
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
van der Horst, H J, de Jonge, A V, Hiemstra, I H, Gelderloos, A T, Berry, D R A I, Hijmering, N J, van Essen, H F, de Jong, D, Chamuleau, M E D, Zweegman, S, Breij, E C W, Roemer, M G M & Mutis, T 2021, ' Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment ', Blood cancer journal, vol. 11, no. 2, 38 . https://doi.org/10.1038/s41408-021-00430-6
Blood cancer journal, 11(2):38. Nature Publishing Group
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
van der Horst, H J, de Jonge, A V, Hiemstra, I H, Gelderloos, A T, Berry, D R A I, Hijmering, N J, van Essen, H F, de Jong, D, Chamuleau, M E D, Zweegman, S, Breij, E C W, Roemer, M G M & Mutis, T 2021, ' Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment ', Blood cancer journal, vol. 11, no. 2, 38 . https://doi.org/10.1038/s41408-021-00430-6
Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from ne
Autor:
Pranav Abraham, Srdan Verstovsek, Francesco Passamonti, Jennifer Lord-Bessen, Shelonitda Rose, Nicolaas Schaap, Claire N. Harrison, Ruben A. Mesa, Moshe Talpaz, Derek Tang, Xiaomei Ye, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Sonja Zweegman, Shien Guo
Publikováno v:
Hemasphere, 5, 5
HemaSphere, Vol 5, Iss 5, p e553 (2021)
Mesa, R A, Schaap, N, Vannucchi, A M, Kiladjian, J J, Passamonti, F, Zweegman, S, Talpaz, M, Verstovsek, S, Rose, S, Abraham, P, Lord-Bessen, J, Tang, D, Guo, S, Ye, X & Harrison, C N 2021, ' Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial ', HemaSphere . https://doi.org/10.1097/HS9.0000000000000553
HemaSphere. Wolters Kluwer Health
HemaSphere
Hemasphere, 5
HemaSphere, Vol 5, Iss 5, p e553 (2021)
Mesa, R A, Schaap, N, Vannucchi, A M, Kiladjian, J J, Passamonti, F, Zweegman, S, Talpaz, M, Verstovsek, S, Rose, S, Abraham, P, Lord-Bessen, J, Tang, D, Guo, S, Ye, X & Harrison, C N 2021, ' Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial ', HemaSphere . https://doi.org/10.1097/HS9.0000000000000553
HemaSphere. Wolters Kluwer Health
HemaSphere
Hemasphere, 5
Patients with myelofibrosis (MF) experience an array of symptoms that impair health-related quality of life (HRQoL). Fedratinib, an oral, selective Janus-kinase 2 (JAK2) inhibitor, was investigated in the randomized, placebo-controlled, phase III JAK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d4b7b132e942c71d0f1cdff8121ffa7
https://repository.ubn.ru.nl/handle/2066/233585
https://repository.ubn.ru.nl/handle/2066/233585
Autor:
Anne T. Gelderloos, Sonja Zweegman, Michael O'Dwyer, Niels W.C.J. van de Donk, Fengzhi Li, Lisa C. Holthof, Richard W.J. Groen, Hilma J. van der Horst, Arwen Stikvoort, Tuna Mutis, Renée Poels
Publikováno v:
HemaSphere
HemaSphere, 5(5). Wolters Kluwer Health
Holthof, L C, Stikvoort, A, van der Horst, H J, Gelderloos, A T, Poels, R, Li, F, Groen, R W J, Zweegman, S, van de Donk, N W C J, O'Dwyer, M & Mutis, T 2021, ' Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant ', HemaSphere, vol. 5, no. 5, pp. e561 . https://doi.org/10.1097/HS9.0000000000000561, https://doi.org/10.1097/HS9.0000000000000561
HemaSphere, Vol 5, Iss 5, p e561 (2021)
HemaSphere, 5(5). Wolters Kluwer Health
Holthof, L C, Stikvoort, A, van der Horst, H J, Gelderloos, A T, Poels, R, Li, F, Groen, R W J, Zweegman, S, van de Donk, N W C J, O'Dwyer, M & Mutis, T 2021, ' Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant ', HemaSphere, vol. 5, no. 5, pp. e561 . https://doi.org/10.1097/HS9.0000000000000561, https://doi.org/10.1097/HS9.0000000000000561
HemaSphere, Vol 5, Iss 5, p e561 (2021)
We have recently shown the strong negative impact of multiple myeloma (MM)-bone marrow mesenchymal stromal cell (BMMSC) interactions to several immunotherapeutic strategies including conventional T cells, chimeric antigen receptor (CAR) T cells, and